Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Keel Labs Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner and 1 distinct art unit, indicating a highly specialized prosecution focus. For a company in this sector, this suggests that their current intellectual property is being evaluated by a single expert group within the USPTO.
The busiest examiner for the company is KRISHNAN, GANAPATHY, who is responsible for 1 pending office action. Since the total number of pending actions is 1, this examiner is the sole individual reviewing the company's active applications. This means the company's immediate success in the Biotechnology & Pharmaceuticals field depends on the specific feedback of KRISHNAN, GANAPATHY. Practitioners should focus their efforts on this 1 distinct examiner, as no other art units are currently influencing the portfolio's trajectory.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18021923 | ALGINATE-BASED POLYMERS AND PRODUCTS, AND THEIR MANUFACTURE | KRISHNAN, GANAPATHY | 1693 | §103DP | Non-Final OA | 1d overdue | Pending | Feb 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKeel Labs Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ganapathy Krishnan has the most, with 1 of Keel Labs Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
